TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1119588
Drug: Psychoanalytically oriented
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoanalytically oriented therapy
Study: 9696508
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy with imipramine
Study: 1583824
Drug: Heparin (H)
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin (H)
Study: 2809693
Drug: Cefixime 200
Normalized name: cefixime 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 200 mg b.i.d. for 10 to 11 days
Study: 2809693
Drug: Cefaclor 500
Normalized name: cefaclor 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 500 mg t.i.d. for 10 to 11 days
Study: 30849250
Drug: Remifentanil patient‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil patient‐controlled intravenous labor analgesia (Group A)
Study: 27966237
Drug: Rilotumumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilotumumab (15 mg/kg), Epirubicin (50 mg/m2), Cisplatin (60 mg/m2), Capecitabine (625 mg/m2 twice daily)
Study: 17828747
Drug: High-dose glucocorticoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose glucocorticoids (prednisone or dexamethasone)
Study: 17828747
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose ACTH (LD-ACTH) stimulation
Study: 16796788
Drug: Panitumumab as
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panitumumab as a single agent
Study: 10078539
Drug: Sildenafil (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (25 mg, 3 times a day for 4 days) + glyceryl trinitrate (0.5 mg/mL infusion)
Study: 10078539
Drug: Sildenafil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (100 mg) + amlodipine
Study: 7735024
Drug: Taper with
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taper with placebo gum
Study: 7735024
Drug: Taper with
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taper with active gum
Study: 1708984
Drug: Normal crystalloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal crystalloid solution (control)
Study: 7238015
Drug: 21-day patch
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 21-day patch testing method
Study: 6108123
Drug: Temazepam 40
Normalized name: Temazepam
DrugBank: Temazepam acetate (DB14671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Temazepam 40 mg
Study: 30361675
Drug: Zein-ALA nanosphere
Normalized name: Zein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zein-ALA nanosphere formulation (F3)
Study: 30361675
Drug: Marketed tablets
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed tablets
Study: 18539007
Drug: 1 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/day of oral DHA
Study: 18539007
Drug: 2 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g/day of oral DHA
Study: 18539007
Drug: 4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/day of oral DHA
Study: 11854727
Drug: WASA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: WASA therapy (warfarin and aspirin)
Study: 11854727
Drug: ASA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA therapy (aspirin alone)
Study: 11854727
Drug: WASA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: WASA therapy
Study: 23558875
Drug: ASA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA therapy
Study: 11854727
Drug: Vein grafts
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vein grafts with WASA therapy
Study: 11854727
Drug: Vein grafts
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vein grafts with ASA therapy
Study: 2209656
Drug: Both agents
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both agents (99mTc‐MIBI and 201Tl)
Study: 31985049
Drug: STS101 5.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: STS101 5.2 mg
Study: 31985049
Drug: STS101 1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: STS101 1.3 mg, 2.6 mg, 5.2 mg
Study: 30563778
Drug: Pridopidine 45
Normalized name: Pridopidine
DrugBank: Pridopidine (DB11947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pridopidine 45 mg
Study: 30563778
Drug: Pridopidine 67.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pridopidine 67.5 mg
Study: 30563778
Drug: Pridopidine 112.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pridopidine 112.5 mg
Study: 26492402
Drug: Dose-escalated intensity-modulated
Normalized name: California intense cedar pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-escalated intensity-modulated radiotherapy (IMRT) after tumour excision
Study: 26492402
Drug: IMPORT HIGH
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMPORT HIGH trial protocol for target volume and OARs dose constraints
Study: 26492402
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of clip information for breast treatment verification
Study: 26492402
Drug: CT guided
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT guided planning with full three-dimensional dose compensation
Study: 21620725
Drug: Normal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal fluid intake (NFI: 2 L/day)
Study: 21620725
Drug: High fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fluid intake (HFI: 4 L/day)
Study: 19499846
Drug: metronidazole 750
Normalized name: metronidazole 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: metronidazole 750 mg/day
Study: 15234855
Drug: Standard condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard condition (twice-yearly Project RESPECT individual counselling)
Study: 12082261
Drug: ACE-inhibitor (Spirapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE-inhibitor (Spirapril - 6 mg/day)
Study: 12082261
Drug: Calcium antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonist (Isradipin - 5 mg/day)
Study: 12082261
Drug: Beta-1-blocker (Talinolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-1-blocker (Talinolol - 100 mg/day)
Study: 12082261
Drug: Diuretic (Indapamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic (Indapamide - 1.5 mg/day)
Study: 9926187
Drug: Oxycodone (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (0.03 mg/kg via PCA, max 3 times/hour, lock-out 10 min) with Paracetamol (1000 mg three times a day)
Study: 9926187
Drug: Oxycodone (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (0.03 mg/kg via PCA, max 3 times/hour, lock-out 10 min) with Ketoprofen (100 mg three times a day)
Study: 9926187
Drug: Oxycodone (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (0.03 mg/kg via PCA)
Study: 2200257
Drug: Metoprolol OROS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol OROS (14/190 mg)
Study: 1974382
Drug: Slow-release (SR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release (SR) metoprolol (200 mg)
Study: 1974382
Drug: Long-acting (LA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting (LA) propranolol (160 mg)
Study: 7011110
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg R 41 468 (acute intravenous administration)
Study: 7011110
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg R 41 468 t.i.d. (oral treatment for 8 days)
Study: 7011110
Drug: R 41
Normalized name: Durahesive Wafer 41m 4x4"
Approvals — FDA: no, EMA: no, PMDA: no
Description: R 41 468 (oral maintenance therapy for 3 weeks)
Study: 30079636
Drug: Both biologics
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both biologics (Proposed biosimilar and Reference pegfilgrastim)
Study: 21221501
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral erythromycin (6 mg/kg/day, in four doses over ten days)
Study: 15542792
Drug: Montelukast 4
Normalized name: montelukast 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 4 or 5 mg once per day for 12 months
Study: 9730852
Drug: Subcutaneous GLP-1
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous GLP-1
Study: 2918846
Drug: Colestipol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colestipol (15 g/d)
Study: 2918846
Drug: Fenofibrate (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (0.25 g/d)
Study: 26678626
Drug: Evacetrapib 130
Normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evacetrapib 130 mg daily in addition to standard medical therapy
Study: 17157756
Drug: Oxygen (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen (4 L/min via nasal prongs)
Study: 17157756
Drug: Oxygen (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen (4 L/min via nasal prongs) in hypoxic patients
Study: 11409185
Drug: Troxerutin 150
Normalized name: troxerutin
DrugBank: Troxerutin (DB13124)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troxerutin 150 mg and carbazochrome 1.5 mg, administered intramuscularly (one ampoule) twice daily for one week
Study: 11409185
Drug: Carbazochrome alone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbazochrome alone, administered intramuscularly (one ampoule) twice daily for one week
Study: 8220919
Drug: Flurbiprofen LAT
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flurbiprofen LAT (40 mg, applied via a non‐woven polyester‐backed patch, 12‐hourly over 14 days)
Study: 8220919
Drug: Control (non-medicated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (non-medicated patch)
Study: 29661699
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg twice daily)
Study: 3026294
Drug: Hydrochlorothiazide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (25 mg twice daily)
Study: 2832575
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg twice daily) + Hydrochlorothiazide (25 mg twice daily)
Study: 31021713
Drug: Estrogen hormone
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen hormone therapy (HT)
Study: 30701936
Drug: Classical triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classical triple scheme of first-line ET (omeprazole 20 mg twice a day, amoxicillin 1000 mg twice a day, clarithromycin 500 mg twice a day) for 10 days
Study: 30701936
Drug: Classical triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classical triple scheme of ET with rebamipide (omeprazole 20 mg twice a day, amoxicillin 1000 mg twice a day, clarithromycin 500 mg twice a day, rebamipide 100 mg 3 times a day) for 10 days
Study: 26244602
Drug: Plant sterol
Normalized name: plant sterol complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterol (PS) consumption (2 g/day for 4 weeks)
Study: 19220533
Drug: One oral
Normalized name: Geone Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: One oral glucose-lowering agent
Study: 19220533
Drug: Two oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two oral glucose-lowering agents
Study: 17014562
Drug: temocapril (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: temocapril (1 mg)
Study: 17014562
Drug: losartan (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan (12.5 mg)
Study: 17014562
Drug: combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination therapy
Study: 10959739
Drug: Fluconazole 100
Normalized name: fluconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 100 mg once weekly
Study: 10959739
Drug: Fluconazole 200
Normalized name: fluconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 200 mg weekly for 4 weeks
Study: 7690382
Drug: Midodrine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine (2.5 mg intravenously)
Study: 29437614
Drug: Vaborbactam alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaborbactam alone (250 to 2000 mg)
Study: 29437614
Drug: Meropenem alone
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Meropenem alone (1000 to 2000 mg)
Study: 29437614
Drug: Vaborbactam and
Normalized name: meropenem and vaborbactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaborbactam and Meropenem in combination
Study: 19707144
Drug: Conventional suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional suspension laryngoscope
Study: 15707491
Drug: Prolonged conservative
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged conservative treatment under supervision of the general practitioner
Study: 12672914
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of soy nuts delivering 6.6 mg daidzein and 9.8 mg genistein
Study: 12672914
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of soy nuts delivering 13.2 mg daidzein and 19.6 mg genistein
Study: 12672914
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g of soy nuts delivering 26.4 mg daidzein and 39.2 mg genistein
Study: 8265876
Drug: Resistive loads
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistive loads increased from 0 to 24 cm H2O/l/s in 1, 3 or 6 steps or decreased in 6 steps
Study: 31950923
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg silodosin for 10 days
Study: 28281972
Drug: 30 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 Gy WBRT + simvastatin 80 mg/day
Study: 22470429
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg/d
Study: 16041191
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin 5000 U subcutaneously (s.q.) twice daily
Study: 16041191
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin 5000 U subcutaneously (s.q.) three times daily
Study: 12446055
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PET and clinical parameters
Study: 10336532
Drug: Ibuprofen (2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (2400 mg p.o.)
Study: 8938155
Drug: HBIg immunoprophylaxis
Normalized name: HBIG
DrugBank: Hepatitis B immune globulin (DB05276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBIg immunoprophylaxis (10,000 IU monthly)
Study: 27506803
Drug: vBloc therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: vBloc therapy
Study: 22366365
Drug: Hyaluronate injection
Normalized name: hyaluronate Injection
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronate injection (once a week for 3 weeks)
Study: 22366365
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (once)
Study: 22366365
Drug: Hyaluronate injection
Normalized name: hyaluronate Injection
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronate injection
Study: 11891668
Drug: Diltiazem slow
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem slow releasing formulation (90 mg)
Study: 11891668
Drug: Diltiazem moderate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem moderate releasing formulation (90 mg)
Study: 11891668
Drug: Diltiazem fast
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem fast releasing formulation (90 mg)
Study: 11891668
Drug: Diltiazem oral
Normalized name: diltiazem Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem oral solution (90 mg)
Study: 9865999
Drug: ML 250
Normalized name: MOXIFLOXACIN 1.6MG/ML 250ML BAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ML 250 IUD
Study: 8588962
Drug: Biodegradable implants
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biodegradable implants (self‐reinforced poly‐L‐lactide wire combined with self‐reinforced polyglycolide screw or self‐reinforced poly‐L‐lactide plug)
Study: 8588962
Drug: Metallic implants
Normalized name: Aluminum metal
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metallic implants (tension band wiring, Kirschner wire and metallic cerclage wire)
Study: 21775106
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate 156 mg
Study: 21775106
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate 234 mg
Study: 19467177
Drug: Omalizumab (minimum,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab (minimum, 0.016 mg/kg per IgE IU/mL every 4 weeks)
Study: 16924047
Drug: Intense pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense pulsed light treatments (3 treatments at 1-month intervals)
Study: 9121357
Drug: Tolterodine 1
Normalized name: tolterodine 1 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 1 or 2 mg twice daily
Study: 30630795
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin calcium (subcutaneous injection for 5 days)
Study: 30630795
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no anti-coagulant agent)
Study: 27272517
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (830 nm wavelength, power 150 mW, spot size 1 cm², 30 s per cm², energy density 4.5 J/cm²)
Study: 18676330
Drug: Temsirolimus, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus, administered at a flat weekly IV dose of 25 mg over 30-60 minutes
Study: 18676330
Drug: Interferon-alpha (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha (standard therapy)
Study: 12505817
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of E-EPA
Study: 8801700
Drug: Low S-citalopram
Normalized name: S-(+)-Citalopram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low S-citalopram due to carbamazepine treatment
Study: 6377873
Drug: Cranial radiation
Normalized name: geranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranial radiation therapy
Study: 6377873
Drug: No cranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: No cranial radiation therapy (Control)
Study: 25603750
Drug: Low‐Level Laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐Level Laser Therapy (LLLT)
Study: 30559886
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MOPs and LLLT
Study: 25013370
Drug: Benidipine (4.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benidipine (4.8 mg/day)
Study: 25013370
Drug: Hydrochlorothiazide (8.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (8.2 mg/day)
Study: 22665131
Drug: Beeswax and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beeswax and herbal oil cream
Study: 19483369
Drug: Stress Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress Management Training (SMT) program with monthly 30-min sessions for 6 months
Study: 18260374
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of pulmicort 2 ml plus 0.5% Aeuromycin solution 10 ml by oxygen driving force, once a day for 3 weeks
Study: 7587848
Drug: Alprazolam (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (up to 2 mg/day)
Study: 2245970
Drug: GH replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH replacement therapy, dosage: around 2 IU/m2/day, duration: 12 months
Study: 2245970
Drug: GH administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GH administration to normal subjects
Study: 29363217
Drug: Clobazam 20
Normalized name: cloBAZam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam 20 mg
Study: 27635023
Drug: Radiopeptide therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiopeptide therapy (90Y‐DOTATOC or 177Lu‐DOTATOC)
Study: 26473561
Drug: Resilience training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resilience training combined with cognitive behavioral and solution-focused counseling
Study: 24220602
Drug: Automated software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated software system for identifying patients eligible for OAC therapy and increasing uptake, used in 23 intervention practices for 6 months.
Study: 24220602
Drug: Automated software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated software system for identifying patients eligible for OAC therapy.
Study: 19742335
Drug: Resection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resection of pancreatic capsule and anterior layer of transverse mesocolon (Group R)
Study: 17719390
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of autologous platelet-poor plasma (PPP) gel
Study: 15121561
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined estrogen plus progestin therapy (2 mg of 17 beta‐estradiol plus 1 mg of norethisterone acetate)
Study: 15121561
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined estrogen plus progestin therapy
Study: 11346146
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha 2b 3 Million Units thrice weekly (group A)